Eisai Co., Ltd.

Eisai Co., Ltd. is a leading global pharmaceutical company headquartered in Tokyo, Japan, with a core mission centered on human health care. Founded in the early 20th century, the company has grown into a major research-driven enterprise with a significant presence in North America, Asia, and Europe. Its strategic focus is on developing innovative treatments in key therapeutic areas, particularly neurology and oncology, aiming to address unmet medical needs worldwide.

History

The company was established on December 6, 1941, by Toyoji Naito, initially operating as a vitamin manufacturer named Nippon Eisai. Its early growth was propelled by the development of intravenous high-calorie infusion therapies, a significant advancement in clinical nutrition. A major turning point came in the 1990s with the launch of Aricept (donepezil), a breakthrough treatment for Alzheimer's disease that achieved global blockbuster status and established the firm's international reputation in central nervous system disorders. Subsequent expansion included the acquisition of MGI Pharma, a biotechnology company based in the United States, strengthening its oncology portfolio. The company has continued to evolve, opening major research centers like the Kashima Research Laboratories and integrating its operations deeply into global markets through partnerships and subsidiaries.

Business segments

The company's operations are divided into two primary business segments. The Pharmaceuticals business encompasses the research, development, marketing, and sales of prescription pharmaceutical products globally, with a heavy emphasis on its neurology and oncology franchises. The Over-the-Counter (OTC) Medicines and Other Products business includes the marketing of consumer health products, primarily in the Japanese domestic market, under well-known brands like Chocola BB. This segment also manages operations related to generic drugs, diagnostic reagents, and medical devices, providing a diversified revenue stream alongside its core innovative pharmaceutical activities.

Products and research

The company's product portfolio is anchored by several key global brands. In neurology, Lecanemab, developed in collaboration with Biogen, represents a landmark monoclonal antibody treatment targeting the underlying pathology of Alzheimer's disease. Other significant neurology products include Fycompa (perampanel) for epilepsy and Belviq, a former treatment for obesity. Its oncology pipeline features Lenvima (lenvatinib), a multi-kinase inhibitor developed for treating thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma, often in combination with Keytruda from Merck & Co.. The firm maintains a robust research and development pipeline focused on dementia, neurodegenerative diseases, and various cancer types, operating major R&D facilities including the Tsukuba Research Laboratories and engaging in numerous alliances with academic institutions and biotech firms.

Corporate affairs

The company is led by Haruo Naito, a grandson of the founder, who has served as CEO since 2005 and has been instrumental in shaping its patient-centric corporate philosophy, known as the human health care (hhc) concept. Its global headquarters are located in Bunkyo, Tokyo, with operational hubs worldwide, including Eisai Inc. in New Jersey, United States, and Eisai Europe Ltd. in Hatfield, United Kingdom. The company is a constituent of the Nikkei 225 stock index and actively engages in corporate social responsibility initiatives, such as the Healthy Aging program and partnerships with organizations like the World Health Organization to combat neglected tropical diseases such as lymphatic filariasis.

Financial performance

For the fiscal year ending March 2024, the company reported consolidated revenue of approximately ¥894.5 billion, demonstrating steady growth driven by its core pharmaceutical products. Its oncology drug Lenvima and its neurology franchise, including Lecanemab, are primary revenue drivers, with significant sales generated in the U.S. market and other key regions like China and Europe. The company consistently invests a high percentage of its revenue back into research and development, with R&D expenses typically exceeding 20% of total sales, underscoring its commitment to long-term innovation. Financial results are significantly influenced by the progress of clinical trials, regulatory approvals from bodies like the U.S. Food and Drug Administration and the European Medicines Agency, and the performance of key licensing partnerships.

Category:Pharmaceutical companies of Japan Category:Companies listed on the Tokyo Stock Exchange